C – REV (HF 10) is an oncolytic virus created by attenuating Herpes simplex virus type 1 (HSV – 1). In December 2016, Takara Bio has concluded an exclusive license agreement on development and sales in Japan with Otsuka Pharmaceutical, and this is now followed with an exclusive license agreement for Korea by Dong-A ST which payed up to 300 mill Yen including lump sum and milestones. Takara Bio keeps manufacturing rights, and the right for investigational drugs for clinical trials and products after marketing will be offered to Dong-A ST for a fee. In Japan, Takara Bio conducted Phase II in which C-REV (HF10) and anti-CTLA4 antibody (ipilimumab) were used in combination for patients with malignant melanoma.

Takara Bio news release, Augus 22, 2018